6 active not recruiting, 6 completed, 1 terminated, 1 unknown. 14 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Active not recruiting 6, Completed 6, Terminated 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Recurrent Glioma: new trials by email Literature Review of Recurrent Glioma trials Research Report on Recurrent Glioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging - Recurrent Glioma, Recurrent WHO Grade 2 Glioma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2024-01-04 | 2026-10-15 |
| Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence Hypofractionated Stereotactic Radiotherapy, Bevacizumab - Glioma, Recurrent Glioma | Phase 2 | Unknown | Huashan Hospital | 42 | 2022-10-01 | 2022-11-10 |
| PARP Inhibition for Gliomas (PI-4G or π4g) Niraparib - Recurrent Glioblastoma, Recurrent Astrocytoma | Phase 2 | Terminated | University of Oklahoma | 15 | 2022-06-09 | 2025-05-23 |
| Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd Talazoparib - Recurrent Glioma, Recurrent Glioblastoma | Phase 2 | Completed | The University of Hong Kong | 33 | 2021-01-01 | 2025-06-11 |
| Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Glioblastoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 89 | 2019-01-30 | 2026-11-13 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-11-13 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2017-08-23 | 2026-11-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-11-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-11-12 |
| Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma Bevacizumab, Minocycline, Radiation - Recurrent Glioma | Phase 1 / Phase 2 | Completed | University of Utah | 22 | 2012-07-06 | 2019-08-16 |
Glioma (14) · Ependymoma (7) · Hepatoblastoma (7) · Histiocytosis, Langerhans-Cell (7) · Lymphoma, Non-Hodgkin (7) · Medulloblastoma (7) · Neuroblastoma (7) · Neuroectodermal Tumors, Primitive, Peripheral (7) · Osteosarcoma (7) · Rhabdoid Tumor (7) · Rhabdomyosarcoma (7) · Sarcoma (7) · Wilms Tumor (7) · Central Nervous System Neoplasms (5) · Sarcoma, Ewing (5)
Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms, Germ Cell and Embryonal (14) · Neoplasms, Glandular and Epithelial (14) · Neoplasms, Nerve Tissue (14) · Neoplasms, Neuroepithelial (14) · Neuroectodermal Tumors (14) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Kidney Diseases (8) · Kidney Neoplasms (8) · Lung Diseases (8)
Magnetic Resonance Spectroscopy (6) · Specimen Handling (6) · Biopsy (4) · X-Rays (4) · Nuclear Medicine Department, Hospital (3) · Phantoms, Imaging (3) · erdafitinib (3) · larotrectinib (3) · olaparib (3) · palbociclib (3) · ulixertinib (3) · Bevacizumab (2) · LY3023414 (2) · tazemetostat (2) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1)
National Cancer Institute (NCI) (10) · Huashan Hospital (1) · The University of Hong Kong (1) · University of Oklahoma (1) · University of Utah (1)
United States (12) · Puerto Rico (8) · Australia (1) · Canada (1) · China (1) · Guam (1) · Hong Kong (1)
Adam Cohen, MD (1) · Aya Helali, MD, PhD (1) · Donald W Parsons (1) · James Battiste, MD (1) · Julia Glade-Bender (1) · Katherine A Janeway (1) · Keith T Flaherty (1) · Kieuhoa T Vo (1) · Patricia M LoRusso (1) · Rajen Mody (1) · Susan N Chi (1) · Theodore W Laetsch (1)
PMID 31401903, PMID 26586415, PMID 32463741, PMID 33048619, PMID 33591402, PMID 35133871, PMID 35138919, PMID 35353553, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 38815151, PMID 38935895, PMID 39298716, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40675687, PMID 40865033, PMID 41066729, PMID 41166674, PMID 42686334
U10CA180886 (7), U10CA180820 (1), U24CA196172 (1), UM1CA186644 (1), UM1CA186689 (1)